Increased risk of laboratory-confirmed and severe influenza in a contemporary cohort of well-treated persons with HIV compared with matched population controls
Background While influenza burden is increased among untreated persons with HIV (PWH), it is unclear if this also applies to well-treated PWH. We investigated the incidence of laboratory-confirmed influenza and severe influenza, i.e. influenza-associated hospitalization and death, in a contemporary cohort of virologically suppressed PWH and matched controls from the Danish general population, and whether HIV status was associated with these outcomes. Methods We included 1,005 virologically suppressed PWH from the Copenhagen Comorbidity in HIV Infection Study and 10,050 matched controls from the Copenhagen General Population Study. Outcome data were obtained from national registries. Incidence rates (IR) per 1,000 person-years (PY) and incidence rate ratios (IRR) were calculated, and cumulative incidences were estimated accounting for competing risks. Associations between HIV status and outcomes were explored using Fine-Gray models. Results Follow-up time was 6,286 PY in PWH and 60,596 PY in matched controls for laboratory-confirmed influenza, and 5,890 PY and 56,015 PY for severe influenza. The IRs per 1,000 PY of laboratory-confirmed influenza were 4.1 (95%CI 2.7-6.1) in PWH and 1.8 (95%CI 1.5-2.1) in controls (IRR 2.3, 95%CI 1.5-3.6, p<0.001). For severe influenza, IRs were 1.9 (95%CI 0.9-3.3) and 0.5 (95%CI 0.4-0.7), and IRR 3.6 (95%CI 1.8-7.2, p<0.001). In competing risk regression models, HIV status was associated with increased risk of laboratory-confirmed influenza (subdistribution hazard rate (sHR) 2.5, 95%CI: 1.6-3.8, p<0.001) and severe influenza (sHR 3.9, 95%CI: 2.0-7.8, p<0.001). Conclusions Even well-treated PWH have higher risk of laboratory-confirmed and severe influenza than the general population, highlighting the importance of preventive measures.
Authors
- Andreas Ronit (ORCID: https://orcid.org/0000-0002-8960-7524)
- Shoaib Afzal (ORCID: https://orcid.org/0000-0002-1442-4694)
- Dina Leth Møller (ORCID: https://orcid.org/0000-0002-3909-0643)
- Andreas Dehlbæk Knudsen (ORCID: https://orcid.org/0000-0002-5349-7829)
- Magnus Glindvad Ahlström (ORCID: https://orcid.org/0000-0001-5546-3959)
- Susanne Dam Nielsen (ORCID: https://orcid.org/0000-0001-6391-7455)
- Josefine Amalie Loft (ORCID: https://orcid.org/0000-0002-8779-803X)
- Børge Grønne Nordestgaard (ORCID: https://orcid.org/0000-0002-1954-7220)
- Thomas Benfield (ORCID: https://orcid.org/0000-0003-0698-9385)
Institutions
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Hvidovre Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/ofid/ofag754
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- Amarin Corporation
- Moderna
- Novo Nordisk
- Rigshospitalet
- Region Hovedstaden
- Shionogi
- Svend Andersen Fonden
- Esperion Therapeutics